Dr. Usmani on DREAMM Trials in Multiple Myeloma

October 9, 2019
Saad Z. Usmani, MD, FACP

Special Issues, Emerging MOAs in Multiple Myeloma: Updates From the 17th IMW, Volume 1, Issue 1

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the DREAMM-1 and DREAMM-2 trials in multiple myeloma.

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the DREAMM-1 and DREAMM-2 trials in multiple myeloma.

In the phase I DREAM-1 trial, patients with relapsed/refractory multiple myeloma received the anti-BCMA antibody-drug conjugate, belantamab mafodotin (GSK2857916). In part 1 of the trial, the recommended phase II dose was determined to be 3.4 mg/kg administered as a 1-hour infusion once every 3 weeks for up to 16 cycles. Notably, responses were reported among patients who were refractory to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies.

Subsequently, the randomized phase II DREAMM-2 trial was launched. In the trial, 196 patients with relapsed/refractory myeloma were randomized to receive 1 of two doses of belantamab mafodotin. In August 2019, belantamab mafodotin was reported to have met the primary endpoint of demonstrating a clinically meaningful overall response rate in patients with relapsed/refractory multiple myeloma, according to topline results from the trial.


x